Managing a Missed Dose of Tezspire (Tezepelumab)
For a patient who missed their Tezspire dose by 5 days, the patient should take the dose now and continue with the original dosing schedule (every 4 weeks from the original scheduled date).
Rationale for Recommendation
- There are no specific evidence-based guidelines on dose adjustments for missed Tezspire doses, similar to the lack of evidence-based guidelines for allergen immunotherapy 1
- The pharmacokinetic profile of tezepelumab shows it is a monoclonal antibody with properties similar to other immunoglobulin G2 antibodies, with a relatively long half-life 2
- The recommended dosing of Tezspire is 210 mg administered subcutaneously every 4 weeks 3, 4
Clinical Considerations
- Maintaining consistent blood levels of tezepelumab is important for continued efficacy in controlling severe asthma 4, 2
- Real-world data shows tezepelumab can reduce exacerbation rates from 3.1 to 0.8 per year, with 59% of patients remaining exacerbation-free at 1 year 5
- Shifting the entire schedule by 5 days would create unnecessary complexity in the medication regimen and potentially lead to further adherence issues 1
Management Algorithm for Missed Tezspire Dose
For doses missed by less than 7 days:
For doses missed by more than 7 days:
- Consult with the prescribing physician before administration
- Consider the patient's current asthma control and risk factors 5
Comparison to Other Medication Classes
- This approach is similar to recommendations for other injectable biologics and consistent with principles applied to:
Practical Patient Education Points
- Encourage the patient to set reminders for future doses to improve adherence 1
- Reassure the patient that a 5-day delay is unlikely to significantly impact the overall effectiveness of treatment 2
- Emphasize the importance of maintaining the regular 4-week dosing schedule for optimal asthma control 4, 6
- Remind the patient to monitor for any changes in asthma symptoms and to use rescue medications as needed 5